← Back to Screener
Larimar Therapeutics, Inc. Common Stock (LRMR)
Price$4.81
Favorite Metrics
Price vs S&P 500 (26W)1.34%
Price vs S&P 500 (4W)-2.59%
Market Capitalization$498.64M
All Metrics
Book Value / Share (Quarterly)$0.94
P/TBV (Annual)1.39x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.36
Price vs S&P 500 (YTD)21.85%
EPS (TTM)$-2.21
10-Day Avg Trading Volume1.41M
EPS Excl Extra (TTM)$-2.21
EPS (Annual)$-2.27
ROI (Annual)-212.17%
Cash / Share (Quarterly)$1.65
ROA (Last FY)-113.60%
EBITD / Share (TTM)$-2.27
ROE (5Y Avg)-82.96%
Cash Flow / Share (Annual)$-1.36
P/B Ratio6.39x
P/B Ratio (Quarterly)4.18x
Net Income / Employee (Annual)$-3
Net Interest Coverage (TTM)-248.46x
ROA (TTM)-101.43%
EPS Incl Extra (Annual)$-2.27
Current Ratio (Annual)2.19x
Quick Ratio (Quarterly)2.12x
3-Month Avg Trading Volume3.27M
52-Week Price Return160.87%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.11
52-Week High$6.42
EPS Excl Extra (Annual)$-2.27
CapEx CAGR (5Y)7.98%
Tangible BV CAGR (5Y)7.23%
26-Week Price Return10.09%
Quick Ratio (Annual)2.12x
13-Week Price Return40.76%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.19x
Enterprise Value$413.226
Book Value / Share Growth (5Y)-30.60%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.65
3-Month Return Std Dev150.15%
Net Income / Employee (TTM)$-3
ROE (Last FY)-212.17%
Net Interest Coverage (Annual)-1613.25x
EPS Basic Excl Extra (Annual)$-2.27
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.21
ROI (TTM)-137.70%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.56
Price vs S&P 500 (52W)125.77%
Year-to-Date Return25.98%
5-Day Price Return-1.23%
EPS Normalized (Annual)$-2.27
ROA (5Y Avg)-56.94%
Month-to-Date Return6.67%
Cash Flow / Share (TTM)$-0.75
EBITD / Share (Annual)$-2.27
LT Debt / Equity (Annual)0.16x
ROI (5Y Avg)-82.96%
LT Debt / Equity (Quarterly)0.13x
EPS Basic Excl Extra (TTM)$-2.21
P/TBV (Quarterly)1.66x
P/B Ratio (Annual)4.18x
Book Value / Share (Annual)$0.94
Price vs S&P 500 (13W)37.90%
Beta1.05x
Revenue / Share (TTM)$0.00
ROE (TTM)-137.70%
52-Week Low$1.73
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.47
4.47
4.47
4.47
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
LRMRLarimar Therapeutics, Inc. Common Stock | — | — | — | — | $4.81 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Larimar Therapeutics is a clinical-stage biotechnology company developing treatments for rare genetic diseases using its proprietary cell-penetrating peptide technology platform. Its lead candidate, CTI-1601, is designed to deliver a critical missing protein directly to the mitochondria of patients with Friedreich's ataxia via subcutaneous injection. The company is advancing a novel treatment approach to address a significant unmet medical need in the rare disease space.